All data are based on the daily closing price as of November 20, 2026
c

Celltrion Pharm

068760.KQ
30.42 USD
-0.57
-1.84%

Overview

Last close
30.42 usd
Market cap
1.35B usd
52 week high
52.45 usd
52 week low
25.63 usd
Target price
101.04 usd

Valuation

P/E
70.5727
Forward P/E
49.505
Price/Sales
6.5486
Price/Book Value
3.8475
Enterprise Value
1.39B usd
EV/Revenue
3.0505
EV/EBITDA
11.8514

Key financials

Revenue TTM
204.10M usd
Gross Profit TTM
60.06M usd
EBITDA TTM
31.79M usd
Earnings per Share
0.44 usd
Dividend
0.15 usd
Total assets
588.61M usd
Net debt
N/A usd

About

Celltrion Pharm, Inc., a pharmaceutical company, develops and sells biosimilars and over-the-counter drugs in South Korea. The company offers hepatotonic, anti-inflammatory, antihistamine, respiratory apparatus, circulary system, digestive and stomachic, hormone/metabolic disease, antibiotic/antimycotic, nutrientia and tonic, immunology, oncology, and other drugs. It serves university hospitals and general pharmacies. Celltrion Pharm Inc. was founded in 1976 and is based in Cheongju-si, South Korea. Celltrion Pharm, Inc. (KOSDAQ:A068760) operates as a subsidiary of Celltrion, Inc.
  • Symbol
    068760.KQ
  • Exchange
    KQ
  • Isin
    KR7068760008
  • Country
    South Korea
  • Sector
    Healthcare
  • Industry
    Drug Manufacturers - Specialty & Generic
  • CEO
    Jung-su Seo
  • Headquarter
    Cheongju-si
  • Web site
    https://www.celltrionph.com
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top